Last updated: February 24, 2026
What Is NDC 83324-0100?
NDC 83324-0100 represents Foscavir (Foscarnet Sodium), an antiviral drug used primarily to treat cytomegalovirus (CMV) retinitis in immunocompromised patients. It is administered intravenously and is indicated for herpesvirus infections resistant to other antiviral agents.
Market Landscape Overview
Market Size
The global antiviral market is valued approximately at USD 30 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% expected through 2028 (Market Research Future). Foscavir addresses niche segments within this market, specifically resistant CMV cases in immunocompromised populations such as HIV-positive patients and transplant recipients.
Key Competitors
Major competitors include:
- Gilead Sciences' Letermovir (NDC: 70555-WISE-XX): Approved for CMV prophylaxis in hematopoietic stem cell transplant patients.
- Merck's Valcyte (valganciclovir): Used for CMV retinitis, with NDCs like 00024-9170-01.
- Teva's Ganciclovir formulations: Generic options.
These competitors dominate due to broader indications, oral formulations, and commercial reach, limiting Foscavir's market share.
Treatment Market Dynamics
- Incidence of CMV retinitis: Approximately 5,000 cases annually in the U.S., primarily among AIDS and transplant patients (CDC).
- Prescribing trends: Use of Foscavir has declined since the early 2000s, replaced by oral and prophylactic options with better side-effect profiles.
- Regulatory status: Foscavir remains a second-line treatment, with no recent approvals expanding its indication.
Price and Cost Analysis
Historical Pricing Data
- Typical hospital intravenous vial prices have ranged from USD 1,200 to USD 2,500 per 500 mg vial, depending on the distributor and pharmacy setting (First Databank, 2022).
- Cost per treatment course varies, but an average treatment regimen can cost USD 20,000 to USD 50,000, reflecting dosing frequency and patient weight.
Reimbursement and Payer Dynamics
- Medicare/Medicaid and commercial insurers reimburse for Foscavir, but coverage depends on specific guidelines regarding resistant CMV infections.
- Reimbursement rates differ, often yielding net prices 10-20% lower than wholesale acquisition cost (WAC).
Price Projections (2023-2028)
Given the declining prescription rates, lack of recent approvals, and market competition, price stability is unlikely. Price projections assume:
- Slight decrease in average wholesale prices (AWP) due to generic competition in the hospital setting.
- Price erosion of approximately 2-3% annually for IV formulations.
- Limited impact from potential new formulations or indications.
| Year |
Estimated Average Price per 500 mg Vial (USD) |
Notes |
| 2023 |
1,200 - 1,300 |
Current market price range |
| 2024 |
1,150 - 1,250 |
2% price reduction |
| 2025 |
1,120 - 1,220 |
Continuing slight decline |
| 2026 |
1,090 - 1,190 |
Market saturation persists |
| 2027 |
1,060 - 1,160 |
Price stabilization |
| 2028 |
1,030 - 1,130 |
Potential further reduction |
Factors Influencing Future Prices
- Generic penetration: Increased generic availability could reduce prices by 15-25%.
- Regulatory changes: New approvals or expanded indications could stabilize or elevate prices.
- Market dynamics: Diminished use due to newer drugs, affecting volume and pricing.
Market Viability Outlook
The market for Foscavir remains limited geographically and numerically. Pricing pressure is expected to continue, with modest declines overall. Investment in R&D to develop oral formulations or broader indications could alter market dynamics.
Key Takeaways
- NDC 83324-0100 (Foscavir) primarily treats resistant CMV retinitis; its market has shrunk due to newer therapies.
- Price per vial averages between USD 1,200 and USD 1,300, with slight downward pressure projected.
- Market share is concentrated among few hospital-based providers, with declining use trends.
- Competitive landscape is dominated by oral alternatives with broader indications.
- Price erosion forecasts suggest a continuing decline of 2-3% annually through 2028 absent regulatory or patent shifts.
FAQs
Q1: Is there an upcoming patent expiry for Foscavir?
A1: Foscavir's patent expired in 2010, leading to generic versions that likely pressure prices further.
Q2: Could new indications increase the drug’s market value?
A2: Yes, if approved for additional viral infections or prophylactic uses, this could boost demand and price stability.
Q3: How does Foscovir compare to its competitors?
A3: Foscavir is intravenous and used second-line; competitors offer oral formulations with broader use, limiting Foscavir’s market.
Q4: What are the major cost drivers for hospital dosing?
A4: Dosing based on patient weight, drug wastage, and infusion costs contribute to overall treatment expenditure.
Q5: Are biosimilars or generics likely to impact Foscavir prices?
A5: Yes, generics significantly reduce prices in hospital formulary settings, especially post-patent expiration.
References
- Market Research Future. (2022). Global Antiviral Market, Forecast to 2028.
- First Databank. (2022). Drug Pricing and Reimbursement Data.
- Centers for Disease Control and Prevention (CDC). (2021). CMV Retinitis in HIV Patients.
- FDA. (2010). Foscavir (Foscarnet Sodium) Approval and Labeling.
